“I wondered if what germinated could be the source of the balm of Gilead,” she said ... to the medicinal plants indigenous to the Middle East. Her research, which uses the Hebrew Bible ...

Subject to regulatory approvals, the generic will be made available in 120 countries, which Gilead stated are high-incidence and resource-limited, being mainly low- to lower-middle-income countries.

KITE-363 is under clinical development by Gilead Sciences and currently in Phase I for Unspecified B-Cell Lymphomas.

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...